Non-Hodgkin's Lymphoma of the Orbit and Ocular Adnexa: Clinical Analysis of 22 Cases.
- Author:
Jae Lyun LEE
1
;
Kyeong Hee LEE
;
Myung Soo HYUN
;
Hwa Sun CHUNG
;
Sei One SHIN
;
Hun Mo RYOO
Author Information
1. Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Yeung Nam University, Division of Hematology-Oncology, Korea. hms@medical.yeungnam.ac.kr
- Publication Type:Original Article
- Keywords:
Orbital lymphoma;
Radiotherapy;
Chemotherapy
- MeSH:
B-Lymphocytes;
Chemoradiotherapy;
Drug Therapy;
Drug Therapy, Combination;
Female;
Humans;
Leukemia, Lymphocytic, Chronic, B-Cell;
Lymphoma;
Lymphoma, B-Cell;
Lymphoma, B-Cell, Marginal Zone;
Lymphoma, Non-Hodgkin*;
Male;
Orbit*;
Radiotherapy;
Retrospective Studies;
Survival Rate;
Treatment Outcome
- From:Korean Journal of Hematology
2001;36(4):286-291
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Non-Hodgkin's lymphoma presenting in the eye is a rare disorder. The aim of this study was to evaluate the clinical features, treatment outcome and complications of patients with non-Hodgkin's lymphoma of the eye. METHODS: We designed retrospective, observational case study. The participants included 22 consecutive patients with non-Hodgkin's lymphoma of the orbit and ocular adnexa treated at the Yeungnam University Hospital between 1992 and 2001. RESULTS: There were 16 males (73%) and 6 females (27%). The median age at ocular presentation was 47. The most common presenting complaint was slowly growing mass at the eye. Histopathologic studies revealed extranodal marginal zone B-cell lymphoma, MALT type in 19 cases (86%), B-cell small lymphocytic lymphoma in one case, diffuse large B-cell lymphoma in one case, and lymphoplasmacytoid lymphoma/immunocytoma in one case. The stages of lymphomas were IA(E) in 17 cases (82%), IIA(E) in 2 cases (9%), IIIA(E) in 2 cases (9%). Radiotherapy alone was employed in 17 cases, chemoradiotherapy was done in 3 cases, chemotherapy alone was administered in one case. Nineteen out of 21 cases (90%) achieved a complete remission, and 5 year survival rate was approximately 90%. Subgroup analysis of the patients with lymphomas in stage IA(E) revealed that complete response rate was 100% and 5 year survival rate was 100% CONCLUSION: Radiotherapy alone can produce durable remission in the majority of the patients with localized extranodal marginal zone B-cell lymphoma, MALT type. However, combination chemotherapy or chemoradiotherapy should be considered in the patients with aggressive lymphomas or indolent lymphomas with systemic manifestation.
